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Storage of dithiothreitol (DTT)-treated red blood cells (RBCs) 
leads to hemolysis. The aim of this study was to compare 
0.1 M DTT with 0.2 M DTT treatment of RBCs and to share 
our experience of providing components to seven patients 
on daratumumab (DARA). This prospective, observational 
study included patients who required RBC transfusion within 
6 months of DARA administration. All patients underwent a 
baseline serologic evaluation followed by a repeat evaluation 
after DARA administration. In addition, use of 0.1 M DTT was 
compared with 0.2 M DTT in terms of concordance of results, 
hemolysis with storage of treated RBCs, and ease of use. A total 
of 22 RBC requisitions were received for seven patients. Antibody 
screen was positive for one patient (anti-C) at baseline; it was 
panreactive for all patients after DARA. Concordance of results 
between the two concentrations was 98.5 percent. Laboratory 
personnel found results obtained with use of 0.1 M DTT–treated 
RBCs easy to interpret. Supernatant hemoglobin was found to be 
significantly greater for 0.2 M DTT–treated RBCs at the sixth day 
of storage. In conclusion, component administration to patients 
on DARA can be done without delay if adequate policies and 
procedures are in place. Use of 0.1 M DTT–pretreated RBCs can 
be used to avoid delay in transfusion and reduce the burden on 
the laboratory of weekly preparation of 0.2 M DTT–treated RBCs. 
Immunohematology 2020;36:157–165.
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Multiple myeloma (MM) is a neoplastic disorder of the 
bone marrow involving the proliferation of plasma cells. 
High-dose chemotherapy followed by autologous stem cell 
transplantation (ASCT) is the mainstay of treatment for newly 
diagnosed, transplant-eligible patients with MM. However, for 
patients who are not eligible for ASCT or those who do not 
opt for ASCT, novel agents in the treatment of MM are being 
developed. Among these drugs, daratumumab (DARA), an 
IgG1к human monoclonal antibody that specifically targets 
human CD38 antigens, was approved by the U.S. Food and 
Drug Administration in November 2016 for cases of relapsed 
and refractory MM.1 CD38 is an integral trans-membrane 
glycoprotein that is overexpressed in myeloma cells, and the 
expression is shared by other lineages including red blood 
cells (RBCs).2 Anti-CD38 mediates via a variety of immune 
mechanisms that are responsible for its anti-myeloma activity 
like complement-dependent cellular cytotoxicity, antibody-
dependent cellular cytotoxicity, immunoregulatory depletion 
of immune-suppressive regulatory T-cells, and antibody-
dependent cellular phagocytosis.3
Transfusion medicine experts have discussed DARA 
because of its interference in serologic testing. The mechanism 
for DARA’s interference in pre-transfusion testing was at first 
unclear; it was discovered that DARA directly binds to CD38 
on RBCs causing panreactivity in serologic testing.4 As a result, 
strategies to overcome this serologic quandary were described 
by many centers, and now guidelines have been laid down 
by AABB and the British Society for Haematology (BSH) for 
handling pre-transfusion testing on samples from patients on 
DARA.4 Treating RBCs with dithiothreitol (DTT) eliminates 
the DARA interference. DTT denatures the cell surface CD38 
by disrupting the disulphide bonds, thus preventing interaction 
of DARA at the RBC surface and allowing for safe transfusion 
of patients on DARA.5,6 DTT treatment of RBCs also denatures 
some of the RBC antigens, such as MER2 and Ge3, and those 
in the Kell, Cartwright, Indian, JMH, Scianna, LW, Lutheran, 
Dombrock, Diego, and Cromer blood group systems—of which 
the most important is K.7 A common practice in these patients, 
therefore, is to transfuse K– RBC units unless the patients 
have been typed as K+. 
DTT treatment of RBCs has the potential to cause 
hemolysis at certain concentrations which can interfere with 
interpretation of results.8–12 Standard DTT treatment of RBCs 
is performed with 0.2 M DTT, although at this concentration 
hemolysis was observed and has been documented. A lower 
concentration (i.e., 0.1 M DTT) can be used for the same 
purpose. In the present study, we share a single center’s 
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experience of pre-transfusion testing in seven patients who 
were candidates for DARA treatment. The aim of this study 
was to compare 0.1 M DTT treatment of RBCs with 0.2 M 
DTT treatment and to share our experience of providing 
components to seven patients receiving DARA.
Materials and Methods
Setting and Design
This prospective, observational study was conducted 
in the Department of Transfusion Medicine at a tertiary 
level health care facility from February 2017 to June 2019. 
In accordance with suggestions described in the literature, 
a protocol was formulated for the institution that required 
all patients suffering from relapsed and refractory MM who 
were prospective candidates for DARA therapy to be sent to 
the Department of Transfusion Medicine by the Hemato-
Oncology and Bone Marrow Transplant team. Approval for 
this study was obtained from the institutional review board 
and institutional ethics committee.
Study Population
Participants were selected based on inclusion and 
exclusion criteria given here. The algorithm of the study is 
illustrated in Figure 1.
inclusion criteriA
• Consecutive patients with MM on DARA therapy who 
gave informed consent for participation.
• Patients who were being treated at the present institute 
only. 
• Patients who required RBC transfusion within 6 months 
of DARA administration and whose request for RBC 
transfusion was received in the RBC serology laboratory 
of the transfusion service.
exclusion criteriA
• Patients who had received RBC transfusion within 3 
months at the time of baseline immunohematologic 
investigation.
• Patients who did not give consent for participation.
• Patients who required emergency/life-saving RBC 
transfusion.
• Patients for whom a requisition form for RBC transfusion 
was not received in the transfusion service.
• Requisitions received for patients who were admitted at 
other institutions.
Serologic Investigation
All serum samples were stored at −80°C for a maximum 
of 6 months for the purpose of testing at a future date in case a 
discrepancy was detected. 
bAseline investigAtion
• ABO and D typing: Automated ABO and D typing were 
performed by solid-phase red cell adherence on an 
automated system (Galileo Neo, Immucor, Norcross, 
GA) using commercial ABO/D reagents (Anti-A, Anti-B, 
Anti-D; Immucor), and reagent RBCs (Referencells; 
Immucor).
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Fig. 1 Algorithm for the study. DARA = daratumumab; RBCs = 
red blood cells; DTT = dithiothreitol; IS = immediate spin; AHG = 
antihuman globulin.








Transfusion service contacted for baseline immunohematologic 
workup (ABO and D typing/extended phenotyping/antibody 
detection test)
Antibody identification performed with 0.2 M DTT–treated panel 
RBCs; corresponding antigen-negative, AHG-crossmatch 
compatible units were issued
Immunohematologic investigation  
(ABO and D typing/antibody detection test)
Antibody detection test done with DTT-pretreated 
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• Antibody detection and identification: Antibody detection 
and identification were performed using column 
agglutination technology (CAT). Commercial cells for 
screening, (Surgiscreen; Ortho Clinical Diagnostics, 
Raritan, NJ), and for identification, (Panel A and Panel 
B; Ortho Clinical Diagnostics), were used. Antihuman 
globulin (AHG) polyspecific cassettes (Ortho BioVue 
cassettes, Ortho Clinical Diagnostics) were used as per 
the manufacturer’s instructions on a semi-automated 
platform (Ortho BioVue, Ortho Clinical Diagnostics).
• Extended phenotyping (C, c, E, e, K, k, Fya, Fyb, Jka, 
Jkb, M, N, S, s, Lea, Leb, P1): Extended phenotyping 
was performed by conventional tube test (CTT) using 
corresponding antisera (Anti-C, Anti-c, Anti-E, Anti-e, 
Anti-K, Anti-Fya, Anti-Fyb, Anti-Jka, Anti-Jkb, Anti-M, 
Anti-N, Anti-S; Immucor and Anti-k, Anti-P1, Anti-s, 
Anti-Lea, Anti-Leb; Ortho Clinical Diagnostics).
• Direct antiglobulin test (DAT): DAT was performed by 
CAT using AHG polyspecific cassettes (Ortho BioVue 
cassettes, Ortho Clinical Diagnostics).
At time of rbc requirement
A blood sample for compatibility testing was sent with the 
request form as part of this center’s routine type and screen 
policy:
• ABO and D typing
• Antibody detection and identification
• DAT
• Crossmatch: For all samples, an AHG crossmatch would 
be performed by CAT using AHG polyspecific cassettes 
(Ortho BioVue cassettes, Ortho Clinical Diagnostics) as 
per manufacturer’s instructions. 
Dtt treAtment of AntiboDy screening rbcs
For patients on DARA, antibody screening RBCs 
pretreated with DTT were always available.
• DTT preparation: 0.1 M DTT was prepared by 
dissolving 0.5 g DTT (DL-DTT, Himedia, Mumbai, 
India) in 32 mL phosphate-buffered saline (PBS) with 
pH adjusted to 8.0. Similarly, 0.2 M DTT was prepared 
by dissolving 1 g DTT in 32 mL PBS with pH 8.0. Both 
concentrations of DTT were prepared simultaneously 
whenever baseline immunohematologic investigations 
were needed for a patient on DARA therapy.
• DTT treatment of RBCs: Ten test tubes were labeled and 
divided into two sets of five test tubes each. One set was 
used for treatment with 0.1 M DTT and the other set 
was used for treatment with 0.2 M DTT. For each set, 
screening cells 1, 2, and 3 were added to three tubes, 
respectively. Positive and negative controls, prepared 
from K+ and E+ reagent RBCs, respectively, were added 
to the fourth and fifth tubes. The controls ensured the 
validity of effective DTT-treatment. DTT-treated RBCs 
were stored at 4°C in PBS and were freshly prepared at 
weekly intervals. However, for the purpose of this study, 
the DTT-treated RBCs could be used up to 14 days from 
preparation.
crossmAtcH requests receiveD, rbc units issueD, AnD 
turnArounD time
Every time a request form was received for these patients, 
an antibody detection test was performed using untreated 
and both 0.1 M and 0.2 M DTT–treated screening RBCs 
simultaneously. A positive antibody detection test warranted 
testing with 0.1 M and 0.2 M DTT–treated panel RBCs follow-
ed by an AHG crossmatch using 0.2 M DTT–treated donor 
RBCs. However, if the antibody detection test was negative 
with the DTT-treated RBCs, an immediate spin crossmatch 
was performed to identify compatible units. The turnaround 
time (TAT) from the time a request form was received to the 
time a donor unit was identified for transfusion was calculated 
for both 0.1 M and 0.2 M DTT–treated RBCs. Table 1 provides 
details of the TAT for all RBC requisitions received during the 
study. All transfusions were actively followed for transfusion-
related adverse events.
Comparison of 0.1 M and 0.2 M DTT–Treated RBCs
The RBCs treated with 0.2 M DTT show hemolysis with 
storage, which can interfere with interpretation of results. 
This finding compels the laboratory to prepare 0.2 M DTT–
treated RBCs frequently, which requires reagents and human 
resources. As an alternative to this, a lower concentration than 
what has been conventionally documented (i.e., 0.1 M DTT) 
was also tested. 
Detection of Hemolysis
To measure the amount of hemolysis, hemoglobin (Hb) 
was measured in the supernatant of reagent screening RBCs 
treated with 0.1 M DTT and 0.2 M DTT using the HemoCue 
Plasma/Low Hb System (HemoCue India, New Delhi, India). 
The day of preparation of DTT-treated RBCs was considered 
day 0. Hemolysis was measured on the day on which a 
requisition form was received for RBC transfusion to a patient 
on DARA.  
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concorDAnce of AntiboDy screen results using 0.1 m AnD 
0.2 m Dtt–treAteD rbcs
Concordance between the results obtained with use of 
0.1 M and 0.2 M DTT–treated antibody screening RBCs was 
recorded. All results were noted, and discrepant results were 
observed microscopically to confirm true agglutination.
survey for eAse of use
Patient samples were preserved and later used for a 
survey. A total of 10 laboratory personnel with a minimum 
work experience of 2 years were given two patient samples 
each. They were asked to perform an antibody detection 
test on patient samples using two different concentrations of 
DTT-treated RBCs: xM and yM. None of the participants were 
aware that xM RBCs were 0.2 M DTT treated and yM RBCs 
were 0.1 M DTT treated. Participants were asked to complete 
a questionnaire based on this exercise. The questionnaire had 
four questions with a 4-point Likert scale for each, where 1 
meant strongly disagree and 4 meant strongly agree. The 
purpose of this questionnaire was to access whether different 
concentrations had any impact on the ease of use by the 
laboratory personnel. Table 2 shows survey results. 
Statistical Analysis
Mean, standard deviation, and range of the supernatant-
free Hb values for both concentrations of DTT were calculated 
separately. Because results of two independent study sample 
groups were compared and the data were normally distributed, 
an independent Student t test was applied. The p value was 
calculated to determine whether the difference was statistically 
significant. A p value of < 0.05 was considered statistically 
significant. 
Results
A total of seven patients were included in the study (five 
men, two women). Mean age of the patients was 54.2 ± 7.6 
years. Results of the immunohematologic investigations 
are provided in Table 3. A total of 22 RBC requisitions were 
received in the study duration for all seven patients, mean 
number of requested RBC units was 7.6 ± 4.2. The mean 
number of RBC units transfused was 7.1 ± 3.9. Details of 
these requisitions are provided in Table 1. Each transfusion 
was actively monitored by Transfusion Medicine residents. All 
transfusions were uneventful. 
Table 1. Turnaround time for all RBC requisitions received during 
the study
Patient
Number of RBC 
requests received
Number of RBC 
units requested
Number of RBC 




1 1 2 2 170
2* 3 7 6 180
172
163
3 2 5 5 168
179





5 2 4 4 171
160









Total 22 53 50
Mean 3.1 ± 1.6 7.6 ± 4.2 7.1 ± 3.9 171.2 ± 12.2
*Patients with difference in number of RBC units requested and number of 
RBC units transfused. This result was due to lesser number of units being 
required to reach desired hematocrit than expected.
RBC = red blood cell.








1 Visible hemolysis with use of xM DTT–
treated RBCs is greater
33 3.3
2 Visible hemolysis with use of yM DTT–
treated RBCs is greater
10 1.0
3 Interpretation of antibody detection test 
results is easier with use of xM DTT–
treated RBCs
28 2.8
4 Interpretation of antibody screening 
results is easier with use of yM DTT–
treated RBCs
37 3.7
*Grading scores ranged from 1 (strongly disagree) to 4 (strongly agree). 
DTT = dithiothreitol; xM = 0.2 M; yM = 0.1 M; RBCs = red blood cells.
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Serologic Investigation
No ABO or D discrepancy was observed for any of the 
study patients, before or after DARA therapy. At baseline, the 
antibody detection test was negative for six patients and pos-
itive (anti-C) for one patient. After DARA administration, the 
antibody detection test performed with untreated screening 
RBCs was positive for all seven patients at the time of receipt 
of each of the 22 requisitions. With DTT-pretreated screening 
RBCs, the antibody detection test for six patients was negative. 
The patient with anti-C in his plasma continued to give a 
positive antibody detection test with DTT-treated screening 
RBCs, and the antibody was identified as anti-C. Antibody 
detection test results with untreated RBCs and with 0.1 M and 
0.2 M DTT–treated RBCs are illustrated in Figure 2A and 2B.
Turnaround Time
Because DTT-pretreated screening RBCs were always 
available in the RBC serology laboratory and six patients had 
a negative antibody screen, these six patients could receive 
transfusions without any delay. Patient 4 (who had anti-C) 
required a little more time for confirming the antibody 
specificity. The transfusion service routinely performs Rh 
and K phenotyping of all donor units; thus antigen-negative 
units could be identified immediately without causing a 
significant increase in TAT. The mean TAT for all requisitions 
received was 171.2 ± 12.2 minutes. The details of turnaround 
time are provided in Table 1.
Table 3. Serologic workup details of patients with MM before and after DARA administration














test (0.1 M DTT–
treated RBCs)
Antibody detection 
test (0.2 M DTT–
treated RBCs) DAT
1 A, D+ Negative Negative 1 20 A, D+ Panreactivity Negative Negative Negative
2 O, D+ Negative Negative 1 15 O, D+ Panreactivity Negative Negative Negative
2 28 O, D+ Panreactivity Negative Negative Negative
3 45 O, D+ Panreactivity Negative Negative Negative
3 AB, D+ Negative Negative 1 21 AB, D+ Panreactivity Negative Negative Negative
2 40 AB, D+ Panreactivity Negative Negative Negative
4 B, D– Positive Negative 1 14 B, D– Panreactivity Positive (Anti-C) Positive (Anti-C) Negative
(Anti-C) 2 30 B, D– Panreactivity Positive (Anti-C) Positive (Anti-C) Negative
3 42 B, D– Panreactivity Positive (Anti-C) Positive (Anti-C) Negative
4 63 B, D– Panreactivity Positive (Anti-C) Positive (Anti-C) Negative
5 97 B, D– Panreactivity Positive (Anti-C) Positive (Anti-C) Negative
5 B, D+ Negative Negative 1 10 B, D+ Panreactivity Negative Negative Negative
2 29 B, D+ Panreactivity Negative Negative Negative
6 B, D+ Negative Negative 1 28 B, D+ Panreactivity Negative Negative Negative
2 46 B, D+ Panreactivity Negative Negative Negative
3 71 B, D+ Panreactivity Negative Negative Negative
4 108 B, D+ Panreactivity Negative Negative Negative
5 149 B, D+ Panreactivity Negative Negative Negative
7 O, D+ Negative Negative 1 18 O, D+ Panreactivity Negative Negative Negative
2 29 O, D+ Panreactivity Negative Negative Negative
3 52 O, D+ Panreactivity Negative Negative Negative
4 84 O, D+ Panreactivity Negative Negative Negative
*No ABO discrepancy detected.
MM = multiple myeloma; DARA = daratumumab; DAT = direct antiglobulin test; RBCs = red blood cells.
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Comparison of 0.1 M and 0.2 M DTT
supernAtAnt-free Hemoglobin meAsurement
Details of Hb estimation are given in Table 4. A statistically 
significant difference (p < 0.05) was observed between 
the mean supernatant Hb observed in both groups. Visible 
hemolysis in the supernatant on the last day of storage of DTT-
treated cells is illustrated in Figure 2C.
concorDAnce of AntiboDy screen results obtAineD witH use 
of 0.1 m AnD 0.2 m Dtt–treAteD rbcs
A concordance of 98.5 percent was found between the 
results obtained by screening RBCs treated with 0.1 M and 
those obtained by screening cells treated with 0.2 M DTT. 
There was only one RBC where a discrepancy was observed; 
the 0.2 M DTT–treated RBC gave a positive result whereas the 
0.1 M DTT–treated RBC gave a negative result. No microscopic 
agglutination was observed. 
survey for eAse of use
Ten laboratory personnel were included in this exercise. 
Based on the responses obtained from the questionnaire, it 
was evident that visible hemolysis was seen more with 0.2 M 
DTT, and the interpretation of antibody detection test results 
was easier with 0.1 M DTT treatment (Table 2).
Discussion
DARA has been known to cause panreactivity with RBCs 
during pre-transfusion testing, and this panreactivity can last 
for several months. RBC treatment with the redox agent DTT 
has been commonly used to denature antigens in certain blood 
group systems, in particular K.5,13 Treating RBCs with DTT 
destroys CD38 and hence removes the interference of DARA 
from pre-transfusion testing.3,4 
Chapuy et al.3 described the method for resolving DARA 
interference with blood compatibility testing. The authors 
found that DARA causes panreactivity in vitro by binding to 
CD38 on reagent RBCs and that treating reagent RBCs with 
DTT is a robust method to negate the DARA interference. The 
authors also found that ABO and D typing were unaffected. 
Similarly, Setia et al.14 reported a case with panreactivity on 
antibody screening and identification panels that was resolved 
with use of 0.2 M DTT. This finding was similar to the present 
study, where no grouping discrepancy was observed, and 
panreactivity was observed with untreated screening RBCs. 
Oostendorp et al.15 noted that DARA treatment of patients 
with MM resulted in false-positive indirect antiglobulin tests 
for 11 patients for 2–6 months after infusion. They performed 
DAT on samples from all 11 patients and found that DAT was 
negative in all of them after DARA administration. Chapuy 
et al.,3 however, reported that the majority of patients had a 
positive DAT with IgG specificity. In the present study, DAT 
was negative for all seven patients. Extended phenotyping 
should be available before DARA is started. This testing is 
done to aid in antibody identification should the patient’s 
Fig. 2 (A) Antibody detection testing showing panreactivity with 
untreated screening RBCs. (B) Antibody detection testing showing 
negative results with 0.1 M and 0.2 M DTT–treated screening RBCs 
using the same patient sample. (C) Visible hemolysis in supernatant 
of 0.2 M DTT–treated RBCs at seventh day of storage. RBCs = red 
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antibody detection test become positive after DARA 
administration and also to transfuse phenotypically matched 
units to avoid alloimmunization.16–18 At our center, extended 
phenotyping was performed on samples from all patients, and 
Rh and K phenotype-matched units were issued, if possible. 
In the landmark SIRIUS trial conducted by Chari et al.,17 47 
patients were included; none of whom had any transfusion 
reaction. In the present study, RBC units were transfused 
under direct supervision of a medical officer and Transfusion 
Medicine resident to look for any transfusion reactions. None 
of the patients experienced any transfusion-related adverse 
events.
The concentration of 0.2 M DTT is known to cause 
hemolysis of RBCs with storage.8–12 The present center has 
experienced the same. Treating screening RBCs every time 
a requisition is received delays transfusion. In an attempt to 
avoid this delay, DTT-treated screening RBCs were stored. 
With storage, however, hemolysis was observed; therefore 
these RBCs were replaced every week, which consumed 
material and manpower. In resource-constrained settings 
such as ours, resources have to be used judiciously. In an 
attempt to resolve this issue, the laboratory tried treating 
RBCs with a lower concentration of DTT. To validate the use 
of 0.1 M DTT instead of 0.2 M DTT, antibody screening was 
simultaneously performed using RBCs treated with both 
concentrations. The amount of hemolysis was also measured at 
both concentrations. We found that use of 0.1 M DTT provides 
the same results as 0.2 M DTT (concordance was 98.5%); 
Table 4. Hemoglobin estimation
Patient number Request number
Days from  
preparation of  
DTT-treated RBCs
Free plasma hemoglobin
0.1 M DTT–treated screening RBCs* 0.2 M DTT–treated screening RBCs*
Cell 1 Cell 2 Cell 3 Cell 1 Cell 2 Cell 3
1 1 2 0.0 0.0 0.0 0.0 0.0 0.0
2 1 4 0.0 0.0 0.0 0.0 0.05 0.03
2 6 0.0 0.01 0.0 0.05 0.05 0.05
3 9 0.0 0.01 0.01 0.06 0.05 0.05
3 1 3 0.0 0.0 0.0 0.02 0.04 0.0
2 7 0.01 0.01 0.0 0.06 0.06 0.07
4 1 4 0.0 0.0 0.0 0.04 0.04 0.05
2 5 0.01 0.0 0.01 0.05 0.06 0.05
3 8 0.0 0.01 0.01 0.06 0.06 0.06
4 9 0.01 0.01 0.02 0.06 0.06 0.06
5 12 0.01 0.01 0.02 0.07 0.06 0.08
5 1 6 0.01 0.0 0.0 0.06 0.04 0.06
2 8 0.01 0.01 0.01 0.08 0.07 0.08
6 1 2 0.0 0.0 0.0 0.01 0.0 0.0
2 3 0.0 0.0 0.0 0.01 0.01 0.02
3 6 0.0 0.0 0.01 0.05 0.05 0.05
4 7 0.01 0.01 0.01 0.06 0.06 0.05
5 8 0.01 0.02 0.01 0.07 0.06 0.05
7 1 5 0.0 0.01 0.0 0.05 0.05 0.05
2 7 0.01 0.01 0.01 0.06 0.05 0.06
3 8 0.01 0.01 0.02 0.06 0.08 0.06
4 11 0.02 0.02 0.02 0.06 0.08 0.07
Mean ± SD 3.1 ± 1.6 6.4 ± 2.7 0.007 ± 0.007 0.05 ± 0.02
p value <0.05
Colored cells highlight the instances when DTT-treated RBCs were used beyond 7 days of storage.
*Antibody screening reagent RBCs (Surgiscreen; Ortho Clinical Diagnostics, Raritan, NJ). DTT = dithiothreitol; RBCs = red blood cells.
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hemolysis was significant in the 0.2 M DTT–treated RBCs at 
6 days after preparation, and the laboratory personnel found 
0.1 M DTT results easier to interpret than results obtained 
using 0.2 M DTT because of the presence of hemolysis in the 
latter. Hemolysis in 0.2 M DTT–treated RBCs was observed 
from 4 to 28 days of preparation in various studies.8–12 Use 
of stabilizing agents like Alsever's solution and PBS at pH 7.3 
have also been tried to preserve DTT-treated RBCs.8–11 In the 
present study, the DTT-treated RBCs were suspended in PBS. 
There was significant hemolysis with 0.2 M DTT–treated 
RBCs. 
Strengths of the present study include easy component 
administration without any delay to patients on DARA be-
cause of the following reasons:
• Good communication between the Hemato-Oncology 
and Transfusion Medicine departments. Baseline 
immunohematologic investigations were available for 
all patients before DARA administration. As has been 
highlighted by Tiwari et al.19 in their commentary 
about approaches to finding a compatible RBC unit 
for patients on DARA, communication between the 
treating physician and Transfusion Medicine physician 
is important to ensure timely patient care.
• DTT-treated antibody screening RBCs were always 
available. This availability led to timely results of 
antibody detection testing.
• The present center performs routine Rh and Kell 
phenotyping of all donor units, which is mentioned on 
the ISBT 128 label. Because most antibodies in mul-
tiply transfused patients belong to these two groups, 
provision of components to our alloimmunized patient 
was also done without delay.
Limitations of the study include exclusion of urgent or 
emergency requests. Also, none of the patients were found to 
be alloimmunized to antigens other than those belonging to 
Rh and Kell blood group systems. Therefore, delay in TAT for 
component provision to such patients could not be determined. 
Lastly, technical staff could discuss the results of their tests 
and answers to the questionnaire among themselves. 
Strengths of this study include quantitative measurement 
of hemolysis, assessment for ease of use of both concentrations 
by the laboratory personnel themselves, timely administration 
of all components due to existence of good interdepartmental 
communication, and well-versed policies and procedures 
in place. Identification of a method for resolution of such 
discrepancies without observing significant hemolysis within 
7 days of the preparation of 0.1 M DTT–treated RBCs was the 
highlight of this study. Nevertheless, further studies need to be 
conducted to determine the minimum, maximum, and average 
duration at which 0.1 M DTT–treated RBCs show significant 
hemolysis.
Conclusion
Component administration to patients on DARA can be 
done without delays if adequate policies and procedures are in 
place, there is good interdepartmental communication between 
Hemato-Oncology and Transfusion Medicine departments, 
and all laboratory personnel are well versed with use of DTT-
treated RBCs. With the present study, we recommend use of 
0.1 M DTT–pretreated RBCs to avoid delay in transfusion and 
reduce the burden on the laboratory of weekly preparation of 
0.2 M DTT–treated RBCs.
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